Skip to main content

Advertisement

SpringerLink
Log in

Serum adiponectin levels between patients with Parkinson’s disease and those with PSP

  • Original Article
  • Published:
Neurological Sciences Aims and scope Submit manuscript

Abstract

Introduction

Adiponectin receptors are expressed in the hypothalamus, brainstem, and basal ganglia. Experimentally, adiponectin was immunopositive in the phosphorylated α-synuclein-positive Lewy bodies in the brain of individuals with Parkinson’s disease (PD), and treatment with recombinant adiponectin suppressed the aggregation of α-synuclein. The close relationship between adiponectin and PD is suggested.

Methods

We assessed whether adiponectin levels may increase in patients with PD and differ in individuals with other neurodegenerative diseases. Blood samples were stored at − 70 °C. Adiponectin levels were measured using a latex turbidimetric immunoassay.

Results

Adiponectin levels of patients with PD (p = 0.019) or PD plus multiple systemic atrophy with predominant parkinsonian features (MSA-P) (p = 0.034) increased compared with those of patients with progressive supranuclear palsy (PSP). A multivariate comparison using ANCOVA showed that the adiponectin level was significantly higher in PD plus MSA-P than in patient with PSP, which is independent of age and BMI (adjusted mean difference of 4.388 μg/ml [95% confidence interval 0.602–8.174, p = 0.024]). A significant positive correlation between adiponectin and HDL-C levels was observed in patients with PD on a single linear regression analysis (β, 0.257; p < 0.001; R2 = 0.271). The results were not significant in patients with MSA-P, PSP, and MSA-P plus PSP.

Conclusions

Adiponectin is likely to play roles in the composition of lipid rafts since the adiponectin level of each patient with alpha-synucleinopathy or PSP differed.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Lara-Castro C, Fu Y, Chung BH, Garvey WT (2007) Adiponectin and the metabolic syndrome: mechanisms mediating risk for metabolic and cardiovascular disease. Curr Opin Lipidol 18:263–270

    Article  CAS  PubMed  Google Scholar 

  2. Parimisetty A, Dorsemans AC, Awada R, Ravanan P, Diotel N, Lefebvre d'Hellencourt C (2016) Secret talk between adipose tissue and central nervous system via secreted factors-an emerging frontier in the neurodegenerative research. J Neuroinflammation 13:67

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  3. Nishimura M, Izumiya Y, Higuchi A, Shibata R, Qiu J, Kudo C, Shin HK, Moskowitz MA, Ouchi N (2008) Adiponectin prevents cerebral ischemic injury through endothelial nitric oxide synthase dependent mechanisms. Circulation 117:216–223

    Article  CAS  PubMed  Google Scholar 

  4. Yang Y, Hu W, Jiang S, Wang B, Li Y, Fan C, Di S, Ma Z, Lau WB, Qu Y (2015) The emerging role of adiponectin in cerebrovascular and neurodegenerative diseases. Biochim Biophys Acta 1852:1887–1894

    Article  CAS  PubMed  Google Scholar 

  5. Markus HS, Tomkins AM, Stern GM (1993) Increased prevalence of undernutrition in Parkinson’s disease and its relationship to clinical disease parameters. J Neural Transm Park Dis Dement Sect 5:117–125

    Article  CAS  PubMed  Google Scholar 

  6. Markus HS, Cox M, Tomkins AM (1992) Raised resting energy expenditure in Parkinson’s disease and its relationship to muscle rigidity. Clin Sci (Lond) 83:199–204

    Article  CAS  Google Scholar 

  7. Quan Li LY, Sun L, Yan J, Yan X, Fang L, Li M, Fan Z (2012) Plasma adiponectin levels in relation to prognosis in patients with angiographic coronary artery disease. Metabolism 61:1803–1808

    Article  PubMed  CAS  Google Scholar 

  8. Scigliano G, Musicco M, Soliveri P, Piccolo I, Ronchetti G, Girotti F (2006) Reduced risk factors for vascular disorders in Parkinson disease patients: a case-control study. Stroke 37:1184–1188

    Article  PubMed  Google Scholar 

  9. Cassani E, Cancello R, Cavanna F, Maestrini S, Di Blasio AM, Liuzzi A, Pezzoli G, Barichella M (2011) Serum adiponectin levels in advanced-stage Parkinson’s disease patients. Parkinsons Dis 2011:624764

    PubMed  PubMed Central  Google Scholar 

  10. Thundyil J, Pavlovski D, Sobey CG, Arumugam TV (2012) Adiponectin receptor signalling in the brain. Br J Pharmacol 165:313–327

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Matsunaga E, Nambu S, Oka M, Iriki A (2013) Differential cadherin expression in the developing postnatal telencephalon of a New World monkey. J Comp Neurol 521:4027–4060

    CAS  PubMed  Google Scholar 

  12. Jo E, McLaurin J, Yip CM, St George-Hyslop P, Fraser PE (2000) Alpha-synuclein membrane interactions and lipid specificity. J Biol Chem 275:34328–34334

    Article  CAS  PubMed  Google Scholar 

  13. Araki K, Yagi N, Ikemoto Y, Yagi H, Choong CJ, Hayakawa H, Beck G, Sumi H, Fujimura H, Moriwaki T, Nagai Y, Goto Y, Mochizuki H (2015) Synchrotron FTIR micro-spectroscopy for structural analysis of Lewy bodies in the brain of Parkinson’s disease patients. Sci Rep 5:17625

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Sekiyama K, Waragai M, Akatsu H, Sugama S, Takenouchi T, Takamatsu Y, Fujita M, Sekigawa A, Rockenstein E, Inoue S, La Spada AR, Masliah E, Hashimoto M (2014) Disease-modifying effect of adiponectin in model of α-synucleinopathies. Ann Clin Transl Neurol 1:479–489

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Li X, Geng J, Liu J (2014) Adiponectin offers protection against L166P mutant DJ-1-induced neuronal cytotoxicity mediated by APPL1-dependent AMPK activation. Int J Neurosci 124:350–361

    Article  CAS  PubMed  Google Scholar 

  16. Hughes AJ, Daniel SE, Kilford L, Lees AJ (1992) Accuracy of clinical diagnosis of idiopathic Parkinson’s disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 55:181–184

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. Köllensperger M, Geser F, Ndayisaba JP, Boesch S, Seppi K, Ostergaard K, Dupont E, Cardozo A, Tolosa E, Abele M, Klockgether T, Yekhlef F, Tison F, Daniels C, Deuschl G, Coelho M, Sampaio C, Bozi M, Quinn N, Schrag A, Mathias CJ, Fowler C, Nilsson CF, Widner H, Schimke N, Oertel W, Del Sorbo F, Albanese A, Pellecchia MT, Barone P, Djaldetti R, Colosimo C, Meco G, Gonzalez-Mandly A, Berciano J, Gurevich T, Giladi N, Galitzky M, Rascol O, Kamm C, Gasser T, Siebert U, Poewe W, Wenning GK, EMSA-SG (2010) Presentation, diagnosis, and management of multiple system atrophy in Europe: final analysis of the European multiple system atrophy registry. Mov Disord 25:2604–2612

    Article  PubMed  Google Scholar 

  18. Gilman S, Wenning GK, Low PA, Brooks DJ, Mathias CJ, Trojanowski JQ, Wood NW, Colosimo C, Dürr A, Fowler CJ, Kaufmann H, Klockgether T, Lees A, Poewe W, Quinn N, Revesz T, Robertson D, Sandroni P, Seppi K, Vidailhet M (2008) Second consensus statement on the diagnosis of multiple system atrophy. Neurology 71:670–676

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Höglinger GU, Respondek G, Stamelou M, Kurz C, Josephs KA, Lang AE, Mollenhauer B, Müller U, Nilsson C, Whitwell JL, Arzberger T, Englund E, Gelpi E, Giese A, Irwin DJ, Meissner WG, Pantelyat A, Rajput A, van Swieten JC, Troakes C, Antonini A, Bhatia KP, Bordelon Y, Compta Y, Corvol JC, Colosimo C, Dickson DW, Dodel R, Ferguson L, Grossman M, Kassubek J, Krismer F, Levin J, Lorenzl S, Morris HR, Nestor P, Oertel WH, Poewe W, Rabinovici G, Rowe JB, Schellenberg GD, Seppi K, van Eimeren T, Wenning GK, Boxer AL, Golbe LI, Litvan I, Movement Disorder Society-endorsed PSP Study Group (2017) Clinical diagnosis of progressive supranuclear palsy: the movement disorder society criteria. Mov Disord 32:853–864

    Article  PubMed  PubMed Central  Google Scholar 

  20. Marin R, Diaz M (2018) Estrogen interactions with lipid rafts related to neuroprotection impact of brain ageing and menopause. Front Neurosci 12:128

    Article  PubMed  PubMed Central  Google Scholar 

  21. Fabelo N, Martín V, Santpere G, Marín R, Torrent L, Ferrer I, Díaz M (2011) Severe alterations in lipid composition of frontal cortex lipid rafts from Parkinson’s disease and incidental Parkinson’s disease. Mol Med 17(9–10):1107–1118

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  22. Dalfó E, Portero-Otín M, Ayala V, Martínez A, Pamplona R, Ferrer I (2005) Evidence of oxidative stress in the neocortex in incidental Lewy body disease. J Neuropathol Exp Neurol 64:816–830

    Article  PubMed  Google Scholar 

  23. Marin R, Fabelo N, Martín V, Garcia-Esparcia P, Ferrer I, Quinto-Alemany D, Díaz M (2017) Anomalies occurring in lipid profiles and protein distribution in frontal cortex lipid rafts in dementia with Lewy bodies disclose neurochemical traits partially shared by Alzheimer’s and Parkinson’s diseases. Neurobiol Aging 49:52–59

    Article  CAS  PubMed  Google Scholar 

  24. Samuel F, Flavin WP, Iqbal S, Pacelli C, Sri Renganathan SD, Trudeau LE, Campbell EM, Fraser PE, Tandon A (2016) Effects of serine 129 phosphorylation on α-synuclein aggregation, membrane association, and internalization. J Biol Chem 291:4374–4385

    Article  CAS  PubMed  Google Scholar 

  25. Wan Z, Mah D, Simtchouk S, Klegeris A, Little JP (2014) Globular adiponectin induces a pro-inflammatory response in human astrocytic cells. Biochem Biophys Res Commun 446(1):37–42

    Article  CAS  PubMed  Google Scholar 

  26. Spranger J, Verma S, Gohring I, Bobbert T, Seifert J, Sindler AL, Pfeiffer A, Hileman SM, Tschöp M, Banks WA (2006) Adiponectin does not cross the blood-brain barrier but modifies cytokine expression of brain endothelial cells. Diabetes 55:141–147

    Article  CAS  PubMed  Google Scholar 

  27. Diniz TA, Aquino Júnior JCJ, Mosele FC, Cabral-Santos C, Lima Junior EA, Teixeira AAS, Lira FS, Rosa Neto JC (2019) Exercise-induced AMPK activation and IL-6 muscle production are disturbed in adiponectin knockout mice. Cytokine 119:71–80

    Article  CAS  PubMed  Google Scholar 

  28. Ouchi N, Parker JL, Lugus JJ, Walsh K (2011) Adipokines in inflammation and metabolic disease. Nat Rev Immunol 11:85–97

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  29. Lindqvist D, Kaufman E, Brundin L, Hall S, Surova Y, Hansson O (2012) Non-motor symptoms in patients with Parkinson’s disease - correlations with inflammatory cytokines in serum. PLoS One 7:e47387

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  30. Scalzo P, Kümmer A, Cardoso F, Teixeira AL (2010) Serum levels of interleukin-6 are elevated in patients with Parkinson’s disease and correlate with physical performance. Neurosci Lett 468:56–58

    Article  CAS  PubMed  Google Scholar 

  31. Qin XY, Zhang SP, Cao C, Loh YP, Cheng Y (2016) Aberrations in peripheral inflammatory cytokine levels in Parkinson disease: a systematic review and meta-analysis. JAMA Neurol 73:1316–1324

    Article  PubMed  Google Scholar 

  32. Nübling G, Schuberth M, Feldmer K, Giese A, Holdt LM, Teupser D, Lorenzl S (2017) Cathepsin S increases tau oligomer formation through limited cleavage, but only IL-6, not cathespin S serum levels correlate with disease severity in the neurodegenerative tauopathy progressive supranuclear palsy. Exp Brain Res 235:2407–2412

    Article  PubMed  CAS  Google Scholar 

  33. Rocha NP, Scalzo PL, Barbosa IG, de Sousa MS, Morato IB, Vieira EL, Christo PP, Reis HJ, Teixeira AL (2014) Circulating levels of adipokines in Parkinson’s disease. J Neurol Sci 339(1–2):64–68

    Article  CAS  PubMed  Google Scholar 

  34. Arai Y, Takayama M, Abe Y, Hirose N (2011) Adipokines and aging. J Atheroscler Thromb 18(7):545–550

    Article  CAS  PubMed  Google Scholar 

  35. Cnop M, Havel PJ, Utzschneider KM, Carr DB, Sinha MK, Boyko EJ, Retzlaff BM, Knopp RH, Brunzell JD, Kahn SE (2003) Relationship of adiponectin to body fat distribution, insulin sensitivity and plasma lipoproteins: evidence for independent roles of age and sex. Diabetologia 46(4):459–469

    Article  CAS  PubMed  Google Scholar 

  36. Bansal N, Charlton-Menys V, Pemberton P, McElduff P, Oldroyd J, Vyas A, Koudsi A, Clayton PE, Cruickshank JK, Durrington PN (2006) Adiponectin in umbilical cord blood is inversely related to low-density lipoprotein cholesterol but not ethnicity. J Clin Endocrinol Metab 91:2244–2249

    Article  CAS  PubMed  Google Scholar 

  37. Chung S, Sawyer JK, Gebre AK, Maeda N, Parks JS (2011) Adipose tissue ATP binding cassette transporter A1 contributes to high-density lipoprotein biogenesis in vivo. Circulation 124:1663–1672

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  38. Zhang Y, McGillicuddy FC, Hinkle CC, O'Neill S, Glick JM, Rothblat GH, Reilly MP (2010) Adipocyte modulation of high-density lipoprotein cholesterol. Circulation 121:1347–1355

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  39. Esposito K, Pontillo A, Di Palo C, Giugliano G, Masella M, Marfella R, Giugliano D (2003) Effect of weight loss and lifestyle changes on vascular inflammatory markers in obese women: a randomized trial. J Am Med Assoc 289:1799–1804

    Article  CAS  Google Scholar 

  40. Baratta R, Amato S, Degano C, Farina MG, Patanè G, Vigneri R, Frittitta L (2004) Adiponectin relationship with lipid metabolism is independent of body fat mass: evidence from both cross-sectional and intervention studies. J Clin Endocrinol Metab 89:2665–2671

    Article  CAS  PubMed  Google Scholar 

  41. Chen H, Zhang SM, Hernán MA, Willett WC, Ascherio A (2003) Weight loss in Parkinson’s disease. Ann Neurol 53:676–679

    Article  PubMed  Google Scholar 

  42. Martínez HR, Escamilla-Ocañas CE, Camara-Lemarroy CR, González-Garza MT, Tenorio-Pedraza JM, Hernández-Torre M (2017) CSF concentrations of adipsin and adiponectin in patients with amyotrophic lateral sclerosis. Acta Neurol Belg 117:879–883

    Article  PubMed  Google Scholar 

  43. Nishizawa H, Shimomura I, Kishida K, Maeda N, Kuriyama H, Nagaretani H, Matsuda M, Kondo H, Furuyama N, Kihara S, Nakamura T, Tochino Y, Funahashi T, Matsuzawa Y (2002) Androgens decrease plasma adiponectin, an insulin-sensitizing adipocyte-derived protein. Diabetes 51:2734–2741

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgments

We are extremely grateful to their corporation of medical staffs in Department of Neurology, Nara Medical University for collecting the blood samples.

Funding

Medical office expenses of Department of Neurology, Nara Medical University. Kataoka H received JSPS KAKENHI Grant Number (15K9356). Sugie K received JSPS KAKENHI Grant Number (16K09728) and Grant-in-Aid for Intractable Disease (H29-030), Ministry of Health, Labour and Welfare of Japan.

Author information

Authors and Affiliations

  1. Department of Neurology, Nara Medical University, 840 Shijo-cho, Kashihara, Nara, 634-8522, Japan

    Hiroshi Kataoka & Kazuma Sugie

Authors
  1. Hiroshi Kataoka
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Kazuma Sugie
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

H Kataoka was responsible for the overall study design and wrote the manuscript. H Kataoka contributed to the acquisition of data and to the analysis and interpretation of the data. H Kataoka and K Sugie contributed to drafting and critical revision of part of the submitted materials.

Corresponding author

Correspondence to Hiroshi Kataoka.

Ethics declarations

Conflict of interest

The authors declare that they have no conflicts of interest.

Ethics statement

This study was approved by the medical ethics committee of Nara Medical University. No investigations or interventions were performed outside of routine clinical care for these patients. As this is case series, without experimental intervention into routine care, the authors confirm that [the approval of an institutional review board]/[patient consent] was not required for this work and no formal research ethics approval was required. Written, fully informed consent was received from the routine clinical care for these patients. We confirm that we have read the Journal’s position on issues involved in ethical publication and affirm that this work is consistent with those guidelines.

Additional information

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Kataoka, H., Sugie, K. Serum adiponectin levels between patients with Parkinson’s disease and those with PSP. Neurol Sci 41, 1125–1131 (2020). https://doi.org/10.1007/s10072-019-04216-4

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10072-019-04216-4

Keywords

Search

Navigation